Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

New England Journal of Medicine

Volumn 352, Issue 25, 2005, Pages 2589-2597

  Winton, Timothy ^a,e   Livingston, Robert ^b   Johnson, David ^c   Rigas, James ^d   Johnston, Michael ^a   Butts, Charles ^a   Cormier, Yvon ^a   Goss, Glenwood ^a   Inculet, Richard ^a   Vallieres, Eric ^b   Fry, Willard ^c   Bethune, Drew ^a   Ayoub, Joseph ^a   Ding, Keyue ^a   Seymour, Lesley ^a   Graham, Barbara ^a   Tsao, Ming Sound ^a   Gandara, David ^b   Kesler, Kenneth ^c   Demmy, Todd ^d   Shepherd, Frances ^a   more..

^a Canada   (Canada)

^b Southwest Oncology Group   (United States)

^c Eastern Cooperative Oncology Group   (United States)

^d Cancer and Leukemia Group B   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ANAMNESIS; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GENDER; HEALTH HAZARD; HEALTH STATUS; HEARING LOSS; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; INFECTION; INTERMETHOD COMPARISON; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SAFETY; SCORING SYSTEM; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VOMITING; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 20544455590     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa043623     Document Type: Article

References (33)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Ponn RB, Lo Cicero J III, Daly BDT. Surgical treatment of nonsmall cell lung cancer. In: Shields TW, Lo Cicero III J, Ponn R, Rusch VW, eds. General thoracic surgery. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2005:1548-87.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
5. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-60.
6. Shepherd FA. Chemotherapy for non-small-cell lung cancer. In: Pearson FG, Cooper JD, Deslauriers J, et al., eds. Thoracic surgery. 2nd ed. New York: Churchill Livingstone, 2002:859-74.
7. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
8. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 1992;340:96-9.
9. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 1975;31:103-15.
10. Tsao M-S, Liu N, Nicklee T, Shepherd F, Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Clin Cancer Res 1997;3:1807-14.
11. Brookmeyer R, Crowley JJ. A confidence interval for median survival time. Biometrics 1982;38:29-41.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Cox DR. Regression models and lifetables. J R Stat Soc [B] 1972;34:187-220.
14. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics 1984;40:797-803.
15. Alam N, Shepherd FA, Winton T, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer 2005;47:385-94.
16. Beziak A, Winton T, Ding K et al. Quality of life in a trial of adjuvant chemotherapy for early stage completely resected non-small cell lung cancer (NCIC CTG BR.10). Lung Cancer 2003;41:Suppl 2:S20. abstract.
17. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000;343:1217-22.
18. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003;95:1453-61.
19. Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-82.
20. Cullen M. Chemotherapy for non-small cell lung cancer: the end of the beginning. Thorax 2003;58:352-6.
21. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123:Suppl 1:226S-243S.
22. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
23. Keller SM, Vangel MG, Adak S, et al. The influence of gender on survival and tumour recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. Lung Cancer 2002;37:303-9.
24. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000;18:623-31.
25. Giaccone G, Splinter TA, Debruyne S, et al. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998;16:2133-41.
26. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:1087-100.
27. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB nonsmall cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 2004;22:Suppl 14S:7019.
28. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systemic review and metaanalysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-62.
29. Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
30. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-6.
31. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8:2407-12.
32. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. J Clin Oncol 2004;22:Suppl 14S:7068.
33. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 2002;13:1515-7.